Clinical trial NCT00319605: Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam
Official title: Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam (Keppra®) (SOLUCION Study)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epilepsy
Keywords: Cross sectional study
acceptability
levetiracetam
oral solution
Keppra
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2006-04-27
Enrollment: 600
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study populaton is defined. See Eligibility Criteria.

Brief summary: Phase IV, observational, post-authorization, cross sectional, open-label, multicenter study to evaluate the acceptability of oral solution of levetiracetam in patients with partial epilepsy as assessed by a questionnaire.


Eligibility criteria: Inclusion Criteria:

* Patients 16 years old or older diagnosed with partial epilepsy with or without generalization receiving levetiracetam oral solution for at least 28 days before the study

Exclusion Criteria:

* Patients with disturbances of the sense of taste and smell that can interfere with the assessment of the parameters of the study

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Alcala De Henares
country: Spain
city: Alcazar De San Juan
country: Spain
city: Alcorcon
country: Spain
city: Alicante
country: Spain
city: Alzira Valencia
country: Spain
city: Avila
country: Spain
city: Badajoz
country: Spain
city: Barcelona
country: Spain
city: Benidorm
country: Spain
city: Caceres
country: Spain
city: Cadz
country: Spain
city: Castellon
country: Spain
city: Coruna
country: Spain
city: Cuenca
country: Spain
city: Elda
country: Spain
city: Eliana
country: Spain
city: Girona
country: Spain
city: Granada
country: Spain
city: Guadalajara
country: Spain
city: Hospitalet Del Llobregat
country: Spain
city: Langreo
country: Spain
city: Las Palmas
country: Spain
city: Leon
country: Spain
city: Lleida
country: Spain
city: Lorca Murcia
country: Spain
city: Lugo
country: Spain
city: Madrid
country: Spain
city: Malaga
country: Spain
city: Manzanares Ciudad Real
country: Spain
city: Manzanares
country: Spain
city: Mataro
country: Spain
city: Merida Badajoz
country: Spain
city: Mostoles
country: Spain
city: Murcia
country: Spain
city: Oviedo
country: Spain
city: Palencia
country: Spain
city: Palmar
country: Spain
city: Palmas de Gran Canaria
country: Spain
city: Pamplona
country: Spain
city: Pontevedra
country: Spain
city: Puerto Del Rosario
country: Spain
city: Roca Del Valles
country: Spain
city: Sabadell
country: Spain
city: Salamanca
country: Spain
city: San Fernando
country: Spain
city: Santa Cruz De Tenerife
country: Spain
city: Sevilla
country: Spain
city: Terrassa
country: Spain
city: Teruel
country: Spain
city: Toledo
country: Spain
city: Valencia
country: Spain
city: Vigo Pontevedra
country: Spain
city: Zamora
country: Spain
city: Zaragoza
country: Spain
Study officials:
affiliation: UCB Pharma
name: Helena Marin Muñoz, MD
role: STUDY_DIRECTOR
References: